Prostate cancer is the most common cancer in men in Germany. The chances of survival are very good compared to most other cancers. However, the consequences of the disease and treatment are often considerable. In particular, physical functional limitations remain long after treatment. To map these symptoms and functions in clinical trials and increasingly in routine clinical practice, the EPIC-26, a patient-reported outcomes questionnaire, has been established, translated into numerous languages, and is part of the ICHOM (International Consortium for Health Outcomes Measurement) standard for localized prostate cancer.

Minimally Important Differences (MIDs) can be used to assess changes in measures collected from the questionnaire. These are values that indicate whether the change is large enough to be noticeable to patients. Despite the high relevance for care and science, no MIDs are available for the German version of the EPIC-26 yet.

The first research objective of the project „Minimally Important Differences and Recommendations for Use in Clinical Practice for the German Version of EPIC-26″ – in short MID-EPIC-D“ – is therefore to statistically determine MIDs for the German version of EPIC-26 using the anchor and distribution method. The second research goal is to develop recommendations for the use of the EPIC-26 together with patients, relatives, and all involved caregiver groups, taking into account the MIDs determined in the first module for treatment planning.

Involved Institutions
Universität Würzburg
German Cancer Society (DKG)
OnkoZert GmbH
Bundesverband Prostatakrebs Selbsthilfe e. V. (BPS)
Haus der Krebs-Selbsthilfe – Bundesverband e. V.

Deutsche Krebshilfe (DKH)

July 2022 – June 2025

see publications

Dr. med. Nora Tabea Sibert
PD Dr. rer. medic. Christoph Kowalski